Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total transaction of $415,013.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $86.23, for a total transaction of $370,961.46.

Palvella Therapeutics Stock Up 3.6%

NASDAQ PVLA traded up $3.49 on Friday, hitting $99.73. The company’s stock had a trading volume of 957,735 shares, compared to its average volume of 138,431. The company’s 50-day moving average is $85.21 and its 200 day moving average is $56.66. The firm has a market cap of $1.18 billion, a PE ratio of -37.92 and a beta of -0.20. Palvella Therapeutics, Inc. has a 1-year low of $11.17 and a 1-year high of $112.00.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, equities analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current year.

Institutional Trading of Palvella Therapeutics

Several large investors have recently made changes to their positions in PVLA. Archer Investment Corp acquired a new position in Palvella Therapeutics during the 3rd quarter worth approximately $28,000. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics during the third quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Palvella Therapeutics during the second quarter valued at approximately $37,000. AlphaQuest LLC acquired a new position in shares of Palvella Therapeutics during the third quarter worth approximately $164,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Oppenheimer raised its price target to $200 from $120, a strong signal from a sell?side firm that can boost bullish interest. Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer
• Positive Sentiment: TD Cowen raised its price target to $133, adding further upward pressure on the stock via another institutional endorsement. TD Cowen Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00
• Positive Sentiment: Market headlines note an analyst upgrade that coincided with a recent sharp move higher in PVLA shares, which likely amplified buying momentum. Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% After Analyst Upgrade
• Neutral Sentiment: HC Wainwright revised down near?term EPS forecasts for FY2027–FY2029 (multiple cuts) but kept a “Buy” rating and a $200 price target — a mixed signal that tempers long?term optimism with weaker near?term profitability projections.
• Negative Sentiment: Lifesci Capital cut its FY2026 EPS estimate (worse expected losses), a negative revision that could weigh on sentiment if the company misses near?term expectations.
• Negative Sentiment: COO Kathleen Goin sold 4,302 shares at an average price of $96.47 (SEC filing), a disclosure investors often view as a cautionary sign even if the sale may be for personal reasons. SEC filing

Analyst Ratings Changes

A number of brokerages have recently issued reports on PVLA. BTIG Research raised their price objective on Palvella Therapeutics from $167.00 to $192.00 and gave the stock a “buy” rating in a research report on Monday. Craig Hallum assumed coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price target for the company. Chardan Capital boosted their price target on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday. UBS Group reiterated a “buy” rating and set a $143.00 price objective on shares of Palvella Therapeutics in a research report on Monday. Finally, TD Cowen boosted their target price on shares of Palvella Therapeutics from $97.00 to $133.00 and gave the company a “buy” rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $155.60.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.